EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSTNIG00000017257
Gene Symbol: PTAFR
2 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSTNIG00000011498
Gene Symbol: PDGFB
2 Cross references
195 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSTNIG00000014225
Gene Symbol: PDGFRB
2 Cross references
198 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSTNIG00000004223
Gene Symbol: PARP2
2 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSTNIG00000000046
Gene Symbol: PARP3
2 Cross references
196 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSTNIG00000014621
Gene Symbol: PARP3
2 Cross references
196 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSTNIG00000004840
Gene Symbol: PORCN
2 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSTNIG00000012507
Gene Symbol: PORCN
2 Cross references
193 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSTNIG00000008628
Gene Symbol: KCNMA1
2 Cross references
235 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSTNIG00000013160
Gene Symbol: KCNMA1
3 Cross references
241 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSTNIG00000016373
Gene Symbol: KCNK2B
2 Cross references
213 Possible Orthologues:

Potassium Channel, Subfamily K, Member 3a

Ensembl ID : ENSTNIG00000016402
Gene Symbol: KCNK3A
2 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).